Sensei Biotherapeutics Net Worth
Sensei Biotherapeutics Net Worth Breakdown | SNSE |
Sensei Biotherapeutics Net Worth Analysis
Sensei Biotherapeutics' net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Sensei Biotherapeutics' financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Sensei Biotherapeutics' overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Sensei Biotherapeutics' net worth analysis. One common approach is to calculate Sensei Biotherapeutics' market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Sensei Biotherapeutics' stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Sensei Biotherapeutics' net worth. This approach calculates the present value of Sensei Biotherapeutics' future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Sensei Biotherapeutics' cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Sensei Biotherapeutics' net worth. This involves comparing Sensei Biotherapeutics' financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Sensei Biotherapeutics' net worth relative to its peers.
Enterprise Value |
|
To determine if Sensei Biotherapeutics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Sensei Biotherapeutics' net worth research are outlined below:
| Sensei Biotherapeutics has some characteristics of a very speculative penny stock | |
| Sensei Biotherapeutics had very high historical volatility over the last 90 days | |
| Sensei Biotherapeutics has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (34.1 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Sensei Biotherapeutics currently holds about 123.71 M in cash with (32.02 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.03, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Roughly 34.0% of the company outstanding shares are owned by corporate insiders | |
| Latest headline from MacroaxisInsider: Acquisition by Gallagher Patrick Stephen of 60000 shares of Sensei Biotherapeutics at 1.43 subject to Rule 16b-3 |
Sensei Biotherapeutics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Sensei Biotherapeutics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Sensei Biotherapeutics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 26th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 26th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Know Sensei Biotherapeutics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Sensei Biotherapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Sensei Biotherapeutics backward and forwards among themselves. Sensei Biotherapeutics' institutional investor refers to the entity that pools money to purchase Sensei Biotherapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | State Street Corp | 2024-12-31 | 25.8 K | Raymond James & Associates | 2024-09-30 | 20 K | Cresset Asset Management, Llc | 2024-12-31 | 19.7 K | Hrt Financial Llc | 2024-12-31 | 11.6 K | Deuterium Capital Management, Llc | 2024-12-31 | 11 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 9.2 K | Tower Research Capital Llc | 2024-12-31 | 5.4 K | Jpmorgan Chase & Co | 2024-12-31 | 705 | Bnp Paribas Arbitrage, Sa | 2024-12-31 | 160 | Ikarian Capital, Llc | 2024-12-31 | 650 K | Vanguard Group Inc | 2024-12-31 | 594.5 K |
Follow Sensei Biotherapeutics' market capitalization trends
The company currently falls under 'Micro-Cap' category with a current market capitalization of 12.32 M.Market Cap |
|
Project Sensei Biotherapeutics' profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.41) | (0.43) | |
| Return On Capital Employed | (0.62) | (0.59) | |
| Return On Assets | (0.41) | (0.43) | |
| Return On Equity | (0.60) | (0.57) |
When accessing Sensei Biotherapeutics' net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Sensei Biotherapeutics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Sensei Biotherapeutics' profitability and make more informed investment decisions.
Please note, the presentation of Sensei Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Sensei Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Sensei Biotherapeutics' management manipulating its earnings.
Evaluate Sensei Biotherapeutics' management efficiency
Sensei Biotherapeutics has return on total asset (ROA) of (0.3019) % which means that it has lost $0.3019 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.5104) %, meaning that it created substantial loss on money invested by shareholders. Sensei Biotherapeutics' management efficiency ratios could be used to measure how well Sensei Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities. As of March 22, 2025, Return On Tangible Assets is expected to decline to -0.43. The current year's Return On Capital Employed is expected to grow to -0.59. The current year's Net Tangible Assets is expected to grow to about 187.4 M, whereas Total Assets are forecasted to decline to about 67.9 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.09 | 2.19 | |
| Tangible Book Value Per Share | 2.09 | 2.19 | |
| Enterprise Value Over EBITDA | (0.34) | (0.35) | |
| Price Book Value Ratio | 0.27 | 0.28 | |
| Enterprise Value Multiple | (0.34) | (0.35) | |
| Price Fair Value | 0.27 | 0.28 | |
| Enterprise Value | 41.4 M | 39.3 M |
Leadership at Sensei Biotherapeutics emphasizes sustainable growth and financial prudence. Our analysis evaluates how these priorities impact the stock's performance in the market.
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Sensei Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Sensei Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Sensei Biotherapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Sensei Biotherapeutics time-series forecasting models is one of many Sensei Biotherapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Sensei Biotherapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Sensei Biotherapeutics Earnings per Share Projection vs Actual
Sensei Biotherapeutics Corporate Management
| Edward Horst | Chief Officer | Profile | |
| Christopher JD | VP Counsel | Profile | |
| Elisabeth Colunio | VP HR | Profile | |
| Lora Pike | Vice Communications | Profile | |
| Steven Fuller | Chief Officer | Profile | |
| Robert MD | Chief Officer | Profile | |
| Erin Colgan | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Sensei Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For information on how to trade Sensei Stock refer to our How to Trade Sensei Stock guide.You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sensei Biotherapeutics. If investors know Sensei will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sensei Biotherapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Sensei Biotherapeutics is measured differently than its book value, which is the value of Sensei that is recorded on the company's balance sheet. Investors also form their own opinion of Sensei Biotherapeutics' value that differs from its market value or its book value, called intrinsic value, which is Sensei Biotherapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sensei Biotherapeutics' market value can be influenced by many factors that don't directly affect Sensei Biotherapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sensei Biotherapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Sensei Biotherapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sensei Biotherapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.